business
GRI Bio Plans 52-Week Study Of GRI-0621 Following Phase 2a IPF Data
GRI Bio reported Phase 2a data supporting GRI-0621 in idiopathic pulmonary fibrosis, with activity across nine mechanistic pillars including anti-fibrotic effects and tissue repair.
Read full article on Rttnews